Phase III study of safety of meningococcal vaccine group A conjugate (MenAfriVac) in healthy Malians

Trial Profile

Phase III study of safety of meningococcal vaccine group A conjugate (MenAfriVac) in healthy Malians

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2015

At a glance

  • Drugs Meningococcal vaccine group A conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
  • Indications Meningococcal group A infections
  • Focus Adverse reactions; Registrational
  • Sponsors PATH
  • Most Recent Events

    • 16 Nov 2015 New trial record
    • 15 Nov 2015 Results published in the Clinical Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top